Specific antitumor immunotherapy in the complex treatment of patients with cerebral hemisphere malignant gliomas

The aim of the research is to investigate activation of antitumor immune response efficiency using professional antigenpresenting autologous dendrite cells in the complex treatment of patients with cerebral hemisphere malignant gliomas. We have analyzed 55 cases of patients with malignant gliomas (41 - glioblastomas, 14 - anaplastic astrocytomas) who received a complex treatment with specific immunotherapy use. All the patients were hospitalized at Late stage of disease and tumor size exceeded 5 cm. Specific antitumor immunotherapy was conducted in accordance with original methodic, including autologous dendrite cells with tumor antigens and tumor cells lysate. Treatment course included intradermal introduction of dendrite cells at the 10-12 day after the operation. The treatment included not less than 3 injections. The course of treatment was repeated every 2-3 months. The immunological status was tested before and after courses of immunotherapy. Specific antitumor immunotherapy included into complex treatment of malignant gliomas allows to increase disease remission, life quality being satisfactory.